ANZCTR - Registration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12626000930381

Ethics application status

Approved

Date submitted

15/07/2026

Date registered

29/07/2026

Date last updated

29/07/2026

Date data sharing statement initially provided

29/07/2026

Type of registration

Prospectively registered

Titles & IDs

Public title

Attitudes, Drivers and Opportunities for Long-Acting Injectable Antiretroviral Therapy: Australian Healthcare Practitioner Perspectives

Scientific title

Attitudes, Drivers and Opportunities for Long-Acting Injectable Antiretroviral Therapy: Australian Healthcare Practitioner Perspectives

Additional trial identifiers [1]

nil

Universal Trial Number (UTN)

Trial acronym

ADOPT

Related trial records

Health condition

Health condition(s) studied:

Human Immunodeficiency Virus (HIV)

Condition category

Condition code

Public Health

Health service research

Infection

Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure

Study type

Observational

Patient registry

False

Target follow-up duration

Target follow-up type

Description of the intervention or exposure

Observational study investigating healthcare practitioner perspectives on factors affecting dissemination, implementation and sustainability of long-acting injectable antiretroviral treatment within Australian clinics. Participation will involve participants completing a single online survey, anticipated to take approximately 15 to 30 minutes. Participants can complete the survey online on a phone, tablet or computer and will only have to complete the survey once.

Intervention code [1]

Not applicable

Description of the comparator or control

No control group.

Control group

Uncontrolled

Outcomes

Primary outcome [1]

Identification of key factors associated with the uptake of long-acting injectable antiretroviral therapy (long-acting Cabotegravir + Rilpivirine) among Australian HIV prescribers, including differences in attitudes, knowledge, and perceived barriers/facilitators. Assessment of attitudes, assessment of knowledge, assessment of perceived barriers and assessment of perceived facilitators will be assessed together as a composite primary outcome.

Timepoint [1]

At time of survey (cross-sectional)

Secondary outcome [1]

Analysis of whether factors associated with the uptake of long-acting injectable antiretroviral therapy (CAP+RPV LA) among Australian HIV prescribers are influenced by prescriber and organisational characteristics. Prescriber and organisational characteristic measures will be assessed together as a composite secondary outcome. Examples of organisational characteristics that will be assessed include: location; service category; funding source (ie. public or privately funded); patient cohort information (ie. size, demographic information); staffing information; details of HIV treatment provision. Examples of prescriber characteristics include: length of time as an S100 (HIV-specific) prescriber; patient caseload; attitudes towards virological failure and medical eligibility for long-acting HIV therapy.

Timepoint [1]

At time of survey (cross-sectional).

Eligibility

Key inclusion criteria

Participants will include APHRA- (Australian Health Practitioner Regulation Agency) registered healthcare practitioners (HCPs) who work within services that provide treatment for People Living with HIV (PLHIV) aged 17 years and over in Australia. This includes specialists, S100 prescribers (including General Practitioners and Nurse Practitioners), registered nurses, and pharmacists.

Minimum age

17 Years

Maximum age

No limit

Sex

Both males and females

Healthy volunteers

Yes

Key exclusion criteria

Participants who are not healthcare practitioners registered with AHPRA and/or do not work in an Australian clinic which provides antiretroviral treatment to people living with HIV who are 17 years or older.

Study design

Purpose

Duration

Selection

Timing

Statistical methods / analysis

Recruitment

Recruitment status

Not yet recruiting

Date of first participant enrolment

Anticipated

1/09/2026

Actual

Date of last participant enrolment

Anticipated

1/03/2027

Actual

Date of last data collection

Anticipated

31/03/2027

Actual

Sample size

Target

100

Accrual to date

Final

Recruitment in Australia

Recruitment state(s)

ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors

Funding source category [1]

Commercial sector/Industry

Name [1]

ViiV Healthcare

Address [1]

Country [1]

Australia

Primary sponsor type

Commercial sector/Industry

Name

ViiV Healthcare

Address

Country

United Kingdom

Secondary sponsor category [1]

Hospital

Name [1]

Royal Perth Hospital

Address [1]

Country [1]

Australia

Ethics approval

Ethics application status

Approved

Ethics committee name [1]

WA Health Central HREC

Ethics committee address [1]

https://www.health.wa.gov.au/Articles/U_Z/WA-Health-Central-HREC

Ethics committee country [1]

Australia

Date submitted for ethics approval [1]

12/05/2026

Approval date [1]

15/05/2026

Ethics approval number [1]

Summary

Brief summary

Long-acting Antiretroviral Therapy (LAI ART) for the treatment of HIV infection has been available in Australia since April 2022, when long-acting injectable cabotegravir and rilpivirine (CAB + RPV) became available on the PBS (Pharmaceutical Benefits Scheme). LAI ART represents a new era of HIV treatment as previous regimens all required a commitment to life-long adherence to daily oral therapy (tablets). In both pre- and post-registrational studies, LAI ART demonstrated efficacy, safety, and tolerability equivalent to standard of care oral therapy with significant transformative benefits in multiple patient reported outcomes, including experience of stigma and wellbeing. Despite this, uptake of LAI ART is highly variable across states and health services. 
ADOPT LAI seeks to understand the attitudes and drivers of oral versus LAI ART uptake among HIV healthcare services across Australia.

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Dr Mina John

Address

Royal Perth Hospital, 197 Wellington Street, Perth, Western Australia, 6000

Country

Australia

Phone

+61 8 9224 2899

Fax

[email protected]

Contact person for public queries

Name

Mina John

Address

Royal Perth Hospital, 197 Wellington Street, Perth, Western Australia, 6000

Country

Australia

Phone

+61 8 9224 2899

Fax

[email protected]

Contact person for scientific queries

Name

Mina John

Address

Royal Perth Hospital, 197 Wellington Street, Perth, Western Australia, 6000

Country

Australia

Phone

+61 8 9224 2899

Fax

[email protected]

Data sharing statement

Will the study consider sharing individual participant data?

No
No IPD sharing reason/comment: Results of this study will be published and available to the public. Further information regarding aggregate de-identified data may be available via written request to the investigators.

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Documents added manually

Documents added automatically